New inhaled insulin could hold promise for people with diabetes

According to diabetes news, a new type of inhaled insulin could be more successful than an earlier form that is not longer produced. The new drug, known as Afrezza, has not yet been approved by the US Food and Drug Administration . It is thought to work faster, manage blood glucose levels more tightly, and lower the risk of hypoglycaemia than all available injectable insulins . Furthermore, the drug may have cracked the danger inherent in its inhaled predecessor, lung problems .
Afrezza is manufactured by pharmaceutical company MannKind Corp. According to their vice-preident of pharmaceutical development, Andrea Leone-Bay: “Afrezza is an ultra-rapid-acting insulin, and clinical studies have shown us that it has the potential to change diabetes therapy, because in the body, Afrezza looks like the insulin that’s normally in a person’s body.”
MannKind were quick to distinguish Afrezza from Exubera, both in terms of manufacture and function. The diabetes treatment is inhaled as a dry powder, and starts acting immediately, reaching its peak within 12 to 15 minutes.

To Top